Antibody response against Pseudomonas aeruginosa and its relationship with immune mediators in the upper and lower airways of cystic fibrosis patients

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Antibody response against Pseudomonas aeruginosa and its relationship with immune mediators in the upper and lower airways of cystic fibrosis patients. / Mauch, Renan M.; Hentschel, Julia; Aanaes, Kasper; Barucha, Anton; Nolasco da Silva, Marcos T.; Levy, Carlos E.; Hoiby, Niels; Mainz, Jochen G.

In: Pediatric Pulmonology, Vol. 55, No. 4, 2020, p. 959-967.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Mauch, RM, Hentschel, J, Aanaes, K, Barucha, A, Nolasco da Silva, MT, Levy, CE, Hoiby, N & Mainz, JG 2020, 'Antibody response against Pseudomonas aeruginosa and its relationship with immune mediators in the upper and lower airways of cystic fibrosis patients', Pediatric Pulmonology, vol. 55, no. 4, pp. 959-967. https://doi.org/10.1002/ppul.24671

APA

Mauch, R. M., Hentschel, J., Aanaes, K., Barucha, A., Nolasco da Silva, M. T., Levy, C. E., Hoiby, N., & Mainz, J. G. (2020). Antibody response against Pseudomonas aeruginosa and its relationship with immune mediators in the upper and lower airways of cystic fibrosis patients. Pediatric Pulmonology, 55(4), 959-967. https://doi.org/10.1002/ppul.24671

Vancouver

Mauch RM, Hentschel J, Aanaes K, Barucha A, Nolasco da Silva MT, Levy CE et al. Antibody response against Pseudomonas aeruginosa and its relationship with immune mediators in the upper and lower airways of cystic fibrosis patients. Pediatric Pulmonology. 2020;55(4):959-967. https://doi.org/10.1002/ppul.24671

Author

Mauch, Renan M. ; Hentschel, Julia ; Aanaes, Kasper ; Barucha, Anton ; Nolasco da Silva, Marcos T. ; Levy, Carlos E. ; Hoiby, Niels ; Mainz, Jochen G. / Antibody response against Pseudomonas aeruginosa and its relationship with immune mediators in the upper and lower airways of cystic fibrosis patients. In: Pediatric Pulmonology. 2020 ; Vol. 55, No. 4. pp. 959-967.

Bibtex

@article{58ee0cfc2bf74ce9bc013125f3a68d0b,
title = "Antibody response against Pseudomonas aeruginosa and its relationship with immune mediators in the upper and lower airways of cystic fibrosis patients",
abstract = "BackgroundThe upper airways (UAW) are a niche and a reservoir of Pseudomonas aeruginosa strains that cause chronic infection of the lower airways (LAW) in cystic fibrosis (CF). Here, we assessed the role of anti‐P. aeruginosa immunoglobulin A (IgA) and IgG antibodies in upper and lower airway infections in cystic fibrosis patients.MethodsNasal lavage fluid and induced sputum samples of 40 CF patients were microbiologically cultured. We searched for correlations between anti‐P. aeruginosa IgA and IgG levels, measured by enzyme‐linked immunosorbent assay (optical density), and unspecific immune mediators in both specimens.ResultsAnti‐P. aeruginosa IgA (median optical density: 0.953 vs 0.298) and IgG (0.120 vs 0.059) were significantly higher in nasal lavage than in sputum, but not significantly different between patients with and without chronic P. aeruginosa infection in UAW. Matrix metallopeptidase‐9 (MMP‐9) in nasal lavage and neutrophil elastase (NE) in sputum were predictors of IgA in nasal lavage and IgA in sputum, respectively. IgA was a predictor of myeloperoxidase (MPO) in nasal lavage. Tissue inhibitor of metalloproteinases‐1 (TIMP‐1) was a predictor of IgG in sputum. IgG, TIMP‐1, and NE in sputum were predictors of IgG in nasal lavage.ConclusionThe anti‐P. aeruginosa IgA response was more prominent in CF patients' UAW, indicating a lower degree of inflammatory responses. Proteases may play a role in the anti‐P. aeruginosa humoral response in the upper and LAW, and anti‐P. aeruginosa IgG may be involved in the crosstalk between upper and lower airways in cystic fibrosis patients.",
keywords = "Pseudomonas aeruginosa, IgA, IgG, lower airways, upper airways, nasal",
author = "Mauch, {Renan M.} and Julia Hentschel and Kasper Aanaes and Anton Barucha and {Nolasco da Silva}, {Marcos T.} and Levy, {Carlos E.} and Niels Hoiby and Mainz, {Jochen G.}",
year = "2020",
doi = "10.1002/ppul.24671",
language = "English",
volume = "55",
pages = "959--967",
journal = "Pediatric pulmonology. Supplement",
issn = "1054-187X",
publisher = "JohnWiley & Sons, Inc.",
number = "4",

}

RIS

TY - JOUR

T1 - Antibody response against Pseudomonas aeruginosa and its relationship with immune mediators in the upper and lower airways of cystic fibrosis patients

AU - Mauch, Renan M.

AU - Hentschel, Julia

AU - Aanaes, Kasper

AU - Barucha, Anton

AU - Nolasco da Silva, Marcos T.

AU - Levy, Carlos E.

AU - Hoiby, Niels

AU - Mainz, Jochen G.

PY - 2020

Y1 - 2020

N2 - BackgroundThe upper airways (UAW) are a niche and a reservoir of Pseudomonas aeruginosa strains that cause chronic infection of the lower airways (LAW) in cystic fibrosis (CF). Here, we assessed the role of anti‐P. aeruginosa immunoglobulin A (IgA) and IgG antibodies in upper and lower airway infections in cystic fibrosis patients.MethodsNasal lavage fluid and induced sputum samples of 40 CF patients were microbiologically cultured. We searched for correlations between anti‐P. aeruginosa IgA and IgG levels, measured by enzyme‐linked immunosorbent assay (optical density), and unspecific immune mediators in both specimens.ResultsAnti‐P. aeruginosa IgA (median optical density: 0.953 vs 0.298) and IgG (0.120 vs 0.059) were significantly higher in nasal lavage than in sputum, but not significantly different between patients with and without chronic P. aeruginosa infection in UAW. Matrix metallopeptidase‐9 (MMP‐9) in nasal lavage and neutrophil elastase (NE) in sputum were predictors of IgA in nasal lavage and IgA in sputum, respectively. IgA was a predictor of myeloperoxidase (MPO) in nasal lavage. Tissue inhibitor of metalloproteinases‐1 (TIMP‐1) was a predictor of IgG in sputum. IgG, TIMP‐1, and NE in sputum were predictors of IgG in nasal lavage.ConclusionThe anti‐P. aeruginosa IgA response was more prominent in CF patients' UAW, indicating a lower degree of inflammatory responses. Proteases may play a role in the anti‐P. aeruginosa humoral response in the upper and LAW, and anti‐P. aeruginosa IgG may be involved in the crosstalk between upper and lower airways in cystic fibrosis patients.

AB - BackgroundThe upper airways (UAW) are a niche and a reservoir of Pseudomonas aeruginosa strains that cause chronic infection of the lower airways (LAW) in cystic fibrosis (CF). Here, we assessed the role of anti‐P. aeruginosa immunoglobulin A (IgA) and IgG antibodies in upper and lower airway infections in cystic fibrosis patients.MethodsNasal lavage fluid and induced sputum samples of 40 CF patients were microbiologically cultured. We searched for correlations between anti‐P. aeruginosa IgA and IgG levels, measured by enzyme‐linked immunosorbent assay (optical density), and unspecific immune mediators in both specimens.ResultsAnti‐P. aeruginosa IgA (median optical density: 0.953 vs 0.298) and IgG (0.120 vs 0.059) were significantly higher in nasal lavage than in sputum, but not significantly different between patients with and without chronic P. aeruginosa infection in UAW. Matrix metallopeptidase‐9 (MMP‐9) in nasal lavage and neutrophil elastase (NE) in sputum were predictors of IgA in nasal lavage and IgA in sputum, respectively. IgA was a predictor of myeloperoxidase (MPO) in nasal lavage. Tissue inhibitor of metalloproteinases‐1 (TIMP‐1) was a predictor of IgG in sputum. IgG, TIMP‐1, and NE in sputum were predictors of IgG in nasal lavage.ConclusionThe anti‐P. aeruginosa IgA response was more prominent in CF patients' UAW, indicating a lower degree of inflammatory responses. Proteases may play a role in the anti‐P. aeruginosa humoral response in the upper and LAW, and anti‐P. aeruginosa IgG may be involved in the crosstalk between upper and lower airways in cystic fibrosis patients.

KW - Pseudomonas aeruginosa

KW - IgA

KW - IgG

KW - lower airways

KW - upper airways

KW - nasal

U2 - 10.1002/ppul.24671

DO - 10.1002/ppul.24671

M3 - Journal article

C2 - 32022432

VL - 55

SP - 959

EP - 967

JO - Pediatric pulmonology. Supplement

JF - Pediatric pulmonology. Supplement

SN - 1054-187X

IS - 4

ER -

ID: 236720934